Wyeth suppresses research on pill, programme claims

The Dutch broadcast comes at a crucial moment because the European Medicines Evaluation Agency is reviewing the next market authorisation of third generation contraceptives. Since the 1995 World Health Organization's collaborative study on cardiovascular side effects of the pill in women in dev...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 2001-03, Vol.322 (7286), p.571-571
Main Author: van Heteren, Godelieve
Format: Article
Language:English
Subjects:
Biomedical Research
Birth control
Contraceptives, Oral, Hormonal - adverse effects
Drug Industry
Europe
Female
Health risk assessment
Humans
Medical research
Netherlands
News
Pharmaceutical industry
Publication Bias
Research Support as Topic
Side effects
Studies
Thromboembolism
Thrombosis
United Kingdom
Venous Thrombosis - chemically induced
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Dutch broadcast comes at a crucial moment because the European Medicines Evaluation Agency is reviewing the next market authorisation of third generation contraceptives. Since the 1995 World Health Organization's collaborative study on cardiovascular side effects of the pill in women in developing countries-which contained the finding that European women taking third generation pills were developing higher incidences of deep venous thrombosis-these pills have come under increasing scrutiny. Dr Allison Jeynes, medical director of Wyeth UK, explaining why the study was not submitted for publication, said: "The data from the third generation oral contraceptive study in question was submitted to the Committee for Proprietary Medicinal Products, the Food and Drugs Administration and regulatory agencies in several other countries.
ISSN:0959-8138
0959-8146
1468-5833
1756-1833
DOI:10.1136/bmj.322.7286.571